FindTrial
Sign In

methylprednisolone IV

DRUG4 trials

Sponsors

Rennes University Hospital, Centre Hospitalier de PAU, Hoffmann-La Roche, Assistance Publique - Hôpitaux de Paris

Conditions

Multiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingNervous System DiseasesParaneoplastic Sensory NeuronopathyPrimary Progressive Multiple SclerosisRelapsing Multiple Sclerosis

Phase 2

Intrathecal Rituximab in Progressive Multiple Sclerosis
CompletedNCT02545959
Centre Hospitalier de PAUMultiple Sclerosis, Chronic Progressive, Nervous System Diseases
Start: 2015-11-30End: 2019-09-02Updated: 2019-10-03
Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy
RecruitingNCT06373211
Assistance Publique - Hôpitaux de ParisParaneoplastic Sensory Neuronopathy
Start: 2025-01-10End: 2028-06-30Target: 21Updated: 2025-02-17

Phase 3

Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses
NCT00984984
Rennes University HospitalMultiple Sclerosis, Relapsing-Remitting
Start: 2008-03-31End: 2014-06-30Target: 200Updated: 2012-12-05
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
CompletedNCT05232825
Hoffmann-La RochePrimary Progressive Multiple Sclerosis, Relapsing Multiple Sclerosis
Start: 2022-05-03End: 2025-06-06Updated: 2025-08-06

Related Papers

Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis
Neurology2025-04-174 citations
Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b <scp>OCARINA</scp> I study
Annals of Clinical and Translational Neurology2024-10-262 citations
OCARINA II, Phase III Study: Results of Subcutaneous Ocrelizumab Administration in Patients with Multiple Sclerosis (S31.006)
Neurology2024-04-098 citations
No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial)
Multiple Sclerosis International2021-03-0819 citations
Literature Commentary
Journal of Neuro-Ophthalmology2016-02-121 citations
Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
2015-06-28100 citations